3 stories mentioning HKG:2526Updated 1d ago
Every FINWIRES story that references HKG:2526, newest first.
Hangzhou Diagens Biotechnology (HKG:2526) reported an attributable loss of 55.9 million yuan for the first half of 2026, widening from a loss of 1.3 million yuan a year earlier, according to a Hong Kong bourse filing on Friday.The medical imaging products maker's loss per share swelled to 0.66 yuan from 0.02 yuan a year ago.Revenue increased year on year to 108.7 million yuan from 89.8 million yuan.
Hangzhou Diagens Biotechnology's (HKG:2526) core product AI AutoVision obtained a Class III Medical Device Registration Certificate from China's National Medical Products Administration, according to a Friday filing with the Hong Kong bourse.The approved indications under the certificate cover chromosome karyotype analysis for the prenatal diagnosis for birth defects using amniotic fluid samples and assisted reproduction using peripheral blood samples.
Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.
